Clinical Trial Update: Gabapentin in Patients at Clinical Risk for Psychosis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 trial of gabapentin in individuals at clinical high risk for psychosis was terminated; results were posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clinical High Risk For Psychosis

Drugs mentioned

• Gabapentin (Gabapentin)

Snippet

Sponsor: New York State Psychiatric Institute | Conditions: Clinical High Risk for Psychosis | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-05-03